Indolequinone antitumor agents: Relationship between quinone structure and rate of metabolism by recombinant human NQO1

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 5, 1998, Pages 545-548

  Beall, Howard D ^a,c   Hudnott, Anna R ^b   Winski, Shannon ^a   Siegel, David ^a   Swann, Elizabeth ^b   Ross, David ^a   Moody, Christopher J ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF EXETER   (United Kingdom)

^c UNIVERSITY OF MONTANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BENZOQUINONE; ANTINEOPLASTIC AGENT; INDOLEQUINONE; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG METABOLISM; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; HUMANS; KINETICS; LUNG NEOPLASMS; NAD(P)H DEHYDROGENASE (QUINONE); QUINONES; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0032478053     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00069-9     Document Type: Article

References (27)

1. 1. Ernster, L. Methods in Enzymology 1967, 10, 309.
2. 2. Ernster, L. Chemica Scripta 1987, 27A, 1.
3. 3. Lind, C.; Cadenas, E.; Hochstein, P.; Ernster, L. Methods in Enzymology 1990, 186, 287.
4. 4. Jaiswal, A. K.; McBride, O. W.; Adesnik, M.; Nebert, D. W. J. Biol. Chem. 1988, 263, 13572.
5. 5. Li, R.; Bianchet, M. A.; Talalay, P.; Amzel, L. M. Proc. Natl. Acad. Sci. 1995, 92, 8846.
6. 6. Ross, D.; Siegel, D.; Beall, H.; Prakash, A. S.; Mulcahy, R. T.; Gibson, N. W. Cancer and Metastasis Rev. 1993, 12, 83.
7. 7. Ross, D.; Beall, H.; Traver, R. D.; Siegel, D.; Phillips, R. M.; Gibson, N. W. Oncol. Res. 1994, 6, 493.
8. 8. Ross, D.; Beall, H. D.; Siegel, D.; Traver, R. D.; Gustafson, D. L. Br. J. Cancer 1996, 74 Suppl. XXVII, S1.
9. 9. Workman, P. Oncol. Res. 1994, 6, 461.
10. 10. Beall, H. D.; Murphy, A. M.; Siegel, D.; Hargreaves, R. H. J.; Butler, J.; Ross, D. Mol. Pharmacol. 1995, 48, 499.
11. 11. Walton, M. I.; Smith, P. J.; Workman, P. Cancer Commun. 1991, 3, 199.
12. 12. Robertson, N.; Stratford, I. J.; Houlbrook, S.; Carmichael, J.; Adams, G. E. Biochem. Pharmacol. 1992, 44, 409.
13. 13. Robertson, N.; Haigh, A.; Adams, G. E.; Stratford, I. J. Eur. J. Cancer 1994, 30A, 1013.
14. 14. Gibson, N. W.; Hartley, J. A.; Butler, J.; Siegel, D.; Ross, D. Mol. Pharmacol. 1992, 42, 531.
15. 15. Gustafson, D. L., Beall, H. D., Bolton, E. M., Waldren C. A.; Ross, D. Mol. Pharmacol. 1996, 50, 728-735; Beall, H. D., Liu, Y., Siegel, D., Bolton, E. M., Gibson, N. W.; Ross, D. Biochem. Pharmacol. 1996, 51, 645.
16. 15. Gustafson, D. L., Beall, H. D., Bolton, E. M., Waldren C. A.; Ross, D. Mol. Pharmacol. 1996, 50, 728-735; Beall, H. D., Liu, Y., Siegel, D., Bolton, E. M., Gibson, N. W.; Ross, D. Biochem. Pharmacol. 1996, 51, 645.
17. 16. Moody, C. J.; O'Sullivan, N.; Stratford, I. J.; Stephens, M. A.; Workman, P.; Bailey, S. M.; Lewis, A. Anti-Cancer Drugs 1994, 5, 367.
18. 17. Cotterill, A. S.; Hartopp, P.; Jones, G. B.; Moody, C. J.; Norton, C. L.; O'Sullivan, N.; Swann, E. Tetrahedron 1994, 50, 7657.
19. 18. Cotterill, A. S.; Moody, C. J.; Mortimer, R. J.; Norton, C. L.; O'Sullivan, N.; Stephens, M. A.; Stradiotto, N. R.; Stratford, I. J.; Swann, E. J. Med. Chem. 1994, 37, 3834.
20. 19. Naylor, M. A.; Swann, E.; Everett, S. A.; Jaffar, M.; Nolan, J.; Robertson, N.; Lockyer, S. D.; Patel, K. B.; Dennis, M. F.; Stratford, M. R. L.; Wardman, P.; Adams, G. E.; Moody, C. J.; Stratford, I. J. J. Med. Chem., submitted for publication.
21. 20. Iyengar, B. S.; Remers, W. A.; Bradner, W. T. J. Med. Chem. 1986, 29, 1864.
22. 21. Franck, R. W.; Tomasz, M. In Chemistry of Antitumor Agents; Wilman, D. E. V., Ed.; Blackie and Son Ltd.: Glasgow, 1990, pp 379-393.
23. 22. Naylor, M. A.; Jaffar, M.; Nolan, J.; Stephens, M. A.; Butler, S.; Patel, K. B.; Everett, S. A.; Adams, G. E.; Stratford, I. J. J. Med. Chem. 1997, 40, 2335.
24. 23. Beall, H. D.; Mulcahy, R. T.; Siegel, D.; Traver, R. D.; Gibson, N. W.; Ross, D. Cancer Res. 1994, 54, 3196.
25. 24. In 1,2-dimethyl indolequinones, 5-aziridinyl derivatives are always easier to reduce than the corresponding 5-methoxy compounds (ref. 18), although this order is reversed in the mitomycin series (ref. 20).
26. 25. Mosmann, T. J. Immunol. Meth. 1983, 65, 55.
27. 26. Traver, R. D.; Siegel, D.; Beall, H. D.; Phillips, R. M.; Gibson, N. W.; Franklin, W. A.; Ross, D. Br. J. Cancer 1997, 75, 69.